FDA Brief

Warning letters Drugs

FDA warning letter to

Signature Formulations, LLC

High riskIssued Jan 21Posted Feb 10Center for Drug Evaluation and Research (CDER)

FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.

What happened

FDA inspected the Phoenix facility from July 21 to 29, 2025 and found shared equipment used for potent ingredients and OTC drugs, inadequate cleaning validation, release testing without adequate chemical or microbiological testing, and quality unit failures. FDA held a teleconference on December 2, 2025 recommending removal of ORL Kid’s Natural Toothpaste and mouthwash from the U.S. market. On December 8, 2025, the company voluntarily recalled ORL kids bubblegum toothpaste lot 250520P4-05/27 and ORL kids bubblegum mouthwash lot 250505P9-05/27 because of potential contamination with exogenous hormones.

What FDA found

  1. The firm made OTC drugs and products with potent active ingredients on shared equipment in a shared facility without adequate separation to prevent cross-contamination.

    21 CFR 211.42(c)
  2. The firm did not have adequate cleaning validation for non-dedicated equipment to prevent cross-contamination with potent ingredients.

    21 CFR 211.67(a)
  3. The firm released finished drug products without adequate laboratory testing for identity, strength, and microorganisms, and did not adequately validate its assay method.

    21 CFR 211.165(a) and 211.165(b)
  4. The quality unit failed to ensure raw material identity testing, laboratory controls, production controls, investigations of non-conformances, and stability testing.

    21 CFR 211.22(a) and 211.22(d)

What FDA wants

FDA tells the company to respond in writing within 15 working days with corrective actions, including independent assessments, risk assessments, cleaning validation, product testing, and quality unit remediation; if it cannot complete actions in that time, it must state why and give a schedule. FDA also recommends a qualified drug consultant and says the company should consider removing or recalling affected products.

Who should pay attention

  • brands that contract with this facility to make OTC drugs
  • retailers and distributors selling ORL children's toothpaste and mouthwash
  • companies using shared equipment or facilities with potent ingredients

This is a summary. Read the original letter on fda.gov.

Signature Formulations, LLC's FDA history

  1. Signature Formulations LLC

    FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.

    High risk

Recalls in the last 12 months

Jan 14 Class II Signature Formulations, LLC
Drug
ORL Kids Mouthwash, Bubblegum Flavor, 16.9 oz. (500ml) per bottle, ORL Labs, LLC, Scottsdale, Arizona USA
cGMP Deviations
Jan 14 Class II Signature Formulations, LLC
Drug
ORL Kids Natural Toothpaste, Bubblegum Flavor, 4 oz (120ml), ORL Labs, LLC, Scottsdale, Arizona USA
cGMP Deviations

Full company page

Similar letters to other companies

  1. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  2. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  3. Dabur India Limited

    FDA cites Dabur India for falsified records, incomplete lab data, and inadequate cleaning and process validation for over-the-counter drugs.

    High risk
  4. 3B Medical, Inc. dba Reach Health, Inc.

    FDA warns Reach Health over unapproved APAP use change and complaint/CAPA failures.

    High risk